Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Hansoh Pharmaceutical has announced that its fifth New Drug Application for Ameile, a third-generation EGFR-TKI drug, has been accepted by China’s National Medical Products Administration. This innovative treatment is aimed at adult patients with specific types of non-small cell lung cancer. Ameile represents a significant development in the pharmaceutical market, boosting Hansoh’s profile in cancer treatment innovations.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.